Intact Vascular Announces Conditional FDA Approval for Tack Optimized Balloon Angioplasty II (TOBA II) Study and Enrollment of First Patients — The TOBA II Study Is Designed to Demonstrate Enhanced Dissection Repair with the Tack Endovascular System™ Following Balloon Angioplasty

September 30, 2015 WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and European IDE clinical trial to investigate use of the Tack Endovascular System as a dissection repair therapy in patients with …

Intact Vascular Announces Conditional FDA Approval for Tack Optimized Balloon Angioplasty II (TOBA II) Study and Enrollment of First Patients — The TOBA II Study Is Designed to Demonstrate Enhanced Dissection Repair with the Tack Endovascular System™ Following Balloon Angioplasty Read More »